Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

12.22USD
4:00pm EDT
Change (% chg)

$0.32 (+2.69%)
Prev Close
$11.90
Open
$11.88
Day's High
$12.32
Day's Low
$11.84
Volume
33,273
Avg. Vol
45,551
52-wk High
$15.75
52-wk Low
$6.85

Select another date:

Tue, May 8 2018

BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36

* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

FDA approves Kindred treatment for problem weight loss in cats

Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

UPDATE 1-FDA approves Kindred treatment for problem weight loss in cats

May 7 Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

FDA approves Kindred's weight-loss ointment for cats

May 7 Kindred Biosciences inc said on Monday the U.S. Food and Drug Administration had approved its topical treatment for unintended weight loss in cats.

BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement

* KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING

BRIEF-Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats

* KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS

BRIEF-Kindred Biosciences Announces Board Appointments

* KINDRED BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DR. ERNEST MARIO AND DR. JOSEPH MCCRACKEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Select another date: